We are happy to share that our portfolio company, Rubedo Life Sciences, has officially dosed the first patient in its Phase 1 clinical trial for RLS-1496, marking a major milestone for the company and the broader senotherapeutics field. The trial is the first to evaluate a GPX4 modulator specifically designed to target pathologic senescent cells in patients with advanced solid tumors.
Instead of treating senescence only as a biomarker of aging, Rubedo is pursuing it as a direct therapeutic target. This Phase 1 study will assess safety and tolerability, with the goal of turning years of research into viable treatments for age-related disease. For more information, check the press release here.
Instead of treating senescence only as a biomarker of aging, Rubedo is pursuing it as a direct therapeutic target. This Phase 1 study will assess safety and tolerability, with the goal of turning years of research into viable treatments for age-related disease. For more information, check the press release here.